ReviewFrontiers in oncology2026

The "ADC-after-ADC" paradigm: navigating cross-resistance and sequencing in breast cancer therapy.

Michael Asare et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.